Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The first use of "lupus" as a disease.
Thomas DE, Enfrein A, Scofield RH. Thomas DE, et al. Lupus. 2025 Jan;34(1):3-9. doi: 10.1177/09612033241306790. Epub 2024 Dec 9. Lupus. 2025. PMID: 39648842
Integrating patient advocacy groups in the development of clinical practice guidelines: comment on the article by Johnson et al.
Gupta N, Carsons SE, Carteron NL, Scofield RH, Lee AS, Thomas DE, Moua T, Ussavarungsi K, St Clair EW, Meehan R, Dunleavy K, Makara M, Hammitt KM. Gupta N, et al. Among authors: thomas de. Arthritis Care Res (Hoboken). 2024 Nov 28. doi: 10.1002/acr.25474. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39605233 No abstract available.
Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
Lee AS, Scofield RH, Hammitt KM, Gupta N, Thomas DE, Moua T, Ussavarungsi K, St Clair EW, Meehan R, Dunleavy K, Makara M, Carsons SE, Carteron NL; Consensus Expert Panel (CEP) Members. Lee AS, et al. Among authors: thomas de. Chest. 2021 Feb;159(2):683-698. doi: 10.1016/j.chest.2020.10.011. Epub 2020 Oct 16. Chest. 2021. PMID: 33075377 Free PMC article.
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, O'Shea JJ, Gadina M, Kaplan MJ. Hasni SA, et al. Nat Commun. 2021 Jun 7;12(1):3391. doi: 10.1038/s41467-021-23361-z. Nat Commun. 2021. PMID: 34099646 Free PMC article. Clinical Trial.
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus.
Hasni S, Temesgen-Oyelakin Y, Davis M, Chu J, Poncio E, Naqi M, Gupta S, Wang X, Oliveira C, Claybaugh D, Dey A, Lu S, Carlucci P, Purmalek M, Manna ZG, Shi Y, Ochoa-Navas I, Chen J, Mukherjee A, Han KL, Cheung F, Koroleva G, Belkaid Y, Tsang JS, Apps R, Thomas DE, Heller T, Gadina M, Playford MP, Li X, Mehta NN, Kaplan MJ. Hasni S, et al. Among authors: thomas de. Ann Rheum Dis. 2022 Aug 1;81(11):1576-84. doi: 10.1136/ard-2022-222658. Online ahead of print. Ann Rheum Dis. 2022. PMID: 35914929 Free PMC article.
106 results